首次在人类中使用二氧化薄膜对无聚合物Everolimus-Eluting支架进行评估
Doo Sun Sim1,2,3, Kyung Hoon Cho2, Dae Young Hyun2
1Department of Cardiovascular Medicine, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju, Korea.
Journal of Korean medical science
|August 27, 2024
概括
这项研究表明,一种新的无聚合物药物释放支架 (DES) 对冠状动脉疾病安全有效. 在8个月后,TIGERevolutioN®支架在患者中显示出较低的晚期光线损失和完全的支架覆盖.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 生物材料科学 生物材料科学
背景情况:
- 聚合物涂层的药物排泄支架 (DES) 可能会由于持续的聚合物存在而阻碍动脉愈合.
- 无聚合物DES提供了改善临床结果和更短的双重抗血小板治疗 (DAPT) 的潜力.
研究的目的:
- 评估一种新型无聚合物常利脱支架 (EES) 的安全性和有效性,用于新冠状动脉病变患者.
- 这项首次对人进行的研究评估了TIGERevolutioN®支架在临床环境中.
主要方法:
- 招募了20名患有新冠肺炎病变的患者.
- 血管造影,光学连贯性断层扫描 (OCT) 和临床评估在8个月后进行.
- 主要终点是在8个月内内置的晚期光量损失 (LLL).
主要成果:
- 在8个月后,TIGERevolutioN®支架显示了0.7 ± 0.4毫米的平均支架内LLL.
- 在所有病变中,OCT显示了29.2 ± 9.4%的支架区域狭窄,在所有病变中完全覆盖了支架支架.
- 在8个月的随访期间,没有报告任何不良心血管事件.
结论:
- 没有聚合物的EES (TIGERevolutioN®) 证明了安全性和有效性.
- 在8个月的随访中,观察到低LLL和优秀的支架支架覆盖率.
相关概念视频
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...


